BofA analyst Joanna Gajuk downgraded Chemed (CHE) to Neutral from Buy with a price target of $450, down from $595.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CHE:
- Chemed reports Q4 adjusted EPS $6.42, consensus $7.03
- Chemed sees FY26 EPS $23.25-$24.25, consensus $25.41
- CHE Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Chemed board authorizes additional $300M for stock repurchases
- Alphabet upgraded, Micron initiated: Wall Street’s top analyst calls